New Monoclonal Antibody Drugs Slow Alzheimer’s Disease Progression – Leqembi & Donanemab (Healthcare Professional)
We are thrilled to share some groundbreaking developments in the field of precision medicine with you. Two promising new drug candidates, Leqembi and Donanemab, have shown great potential in slowing the progression of Alzheimer’s disease, marking a significant step forward in tackling this challenging condition.
Precision Medicine: Riding the Wave of ChatGPT- PMWC Jan. 24-26, 2024 SAVE THE DATE
At PMWC 2024, we will explore how ChatGPT and similar LLMs can unlock the full potential of precision medicine. Together, we will address the challenges associated with implementation, including ensuring up-to-date content, incorporating human oversight, mitigating potential data biases, and ensuring compliance with the Health Insurance Portability and Accountability Act (HIPAA).
Letter from Vice Chancellor Keith Yamamoto – Public-Private Collaboratives: Essential Elements of Precision Medicine
“Achieving precision medicine depends on federal resources to de-risk bold development, prototype impactful technologies, advance manufacturing, and put public good and public health on solid economic ground.” “Science the Endless Frontier”, the 1945 report prepared for President Roosevelt by Vannevar Bush, established the U.S. science policy framework that stands to this day: the federal government […]
IN 3 WEEKS- RWE/D Impacting Healthcare Decisions, But the Scientific Community Has to Get Active! More at PMWC Jan 25-27
Real-world evidence (RWE)-based approaches will increasingly influence clinical decision-making as real-world data (RWD) analysis methods advance, along with expanding acquisition, aggregation, and harmonization of RWD from traditional and novel sources. Growth of real-world datasets will elevate statistical power and generalizability, and ultimately is expected to enhance disease prevention and management across clinical domains and populations. […]
Gene and Cell Therapies – From Promise to Reality -Hear More at PMWC Next month (Jan 25-27, 2023 Silicon Valley)
Gene-modified cell therapies – often also referred to as ex vivo gene therapies – consist of specific cells that are genetically modified outside the body being administered as a therapeutic in order to help the patient fight a particular disease. In the context of gene therapy new genetic material can be introduced to repair an […]
Note from Cindy Perettie re PMWC 2023’s Liquid Biopsy Track
The biggest winner of COVID was liquid biopsy (LB), as interventional surgeries for biopsies simply weren’t happening during much of the pandemic. LB was a phenomenal solution and the restrictions due to COVID certainly propelled its advancement during the last couple of years. We had the opportunity to leverage LB for cancer patients showing the […]
AI in Healthcare: A critical analysis of the rapid growth in the volume of healthcare data. Hear more at January’s PMWC 2023 Silicon Valley
“We are in an era when the volume of healthcare data is growing at lightning speed but our ability to gain insights from that data for improved health outcomes remains far behind. Barriers are many and include silos of information, poor data quality from non-structured EHRs, underutilized genomics, and continued healthcare inequities. Bringing together stakeholders […]
80% of Rare Diseases are Linked to Differences in DNA: hear from Genome England, AOU, MVP, AZ 2M study – PMWC23 FULL PROGRAM IS LIVE
Large-scale omics initiatives (i.e., population studies) that generate and collect human genomic data are evolving rapidly across the globe in both the private and public sectors – here are some amazing genome study numbers associated with roughly 190 global large-scale genomic initiatives (status quo February 2020): • ~38 million genomes or fractions of genomes had been […]
First Pediatric Patient Ever to Receive CAR T-Cell Therapy Is 10 Years Cancer Free
Ten years ago the first child received CAR T-cell therapy to treat acute lymphoblastic leukemia, the most common childhood cancer. Today she is 10 years cancer free. While these cell- and gene-therapies have shown tremendous promise through successful outcomes in the cases known to date, the use of new cell- and gene-based therapies has been […]
PGx Requires Continuous Development of Clinical Strategies, more from Mary Relling of St. Jude, Track Chair on January 27, 2023
“Clinical implementation of pharmacogenetic testing is no longer held back primarily by a lack of evidence supporting its use but remains relatively rare for practical reasons. In the next 3 years, implementation can be facilitated by continued development of clinical guidelines and informatics tools that can work across platforms, increased uptake by professional societies, continued […]
